Intangible Assets and Goodwill

9 Months Ended

Sep. 29, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS AND GOODWILL

Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2018. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.



(Dollars in Millions)	September 29, 2019		December 30, 2018
Intangible assets with definite lives:
Patents and trademarks — gross	$	36,114	35,194
Less accumulated amortization	12,158		9,784
Patents and trademarks — net	23,956		25,410
Customer relationships and other intangibles — gross	21,845		21,334
Less accumulated amortization	9,120		8,323
Customer relationships and other intangibles — net	12,725		13,011
Intangible assets with indefinite lives:
Trademarks	6,875		6,937
Purchased in-process research and development ⁽¹⁾	4,290		2,253
Total intangible assets with indefinite lives	11,165		9,190
Total intangible assets — net	$	47,846	47,611

⁽¹⁾In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion.

Goodwill as of September 29, 2019 was allocated by segment of business as follows:



(Dollars in Millions)	Consumer			Pharm		Med Devices		Total
Goodwill at December 30, 2018	$	8,670		9,063		12,720		30,453
Goodwill, related to acquisitions	1,191			—		2,018		3,209
Currency translation/Other	(266		)	(86	)	(19	)	(371	)
Goodwill at September 29, 2019	$	9,595		8,977		14,719		33,291

The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion for each of the fiscal third quarters ended September 29, 2019 and September 30, 2018. The amortization expense of amortizable intangible assets included in cost of products sold was $3.3 billion for each of the fiscal nine months ended September 29, 2019 and September 30, 2018. The estimated amortization expense for the five succeeding years approximates $4.4 billion, before tax, per year. Intangible asset write-downs are included in Other (income) expense, net.

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.